P1178: BRENTUXIMAB VEDOTIN IN COMBINATION WITH LENALIDOMIDE AND RITUXIMAB IN PATIENTS WITH RELAPSED/REFRACTORY DLBCL: SAFETY AND EFFICACY RESULTS FROM THE SAFETY RUN-IN PERIOD OF THE PHASE 3 ECHELON-3 STUDY

P1178: BRENTUXIMAB VEDOTIN IN COMBINATION WITH LENALIDOMIDE AND RITUXIMAB IN PATIENTS WITH RELAPSED/REFRACTORY DLBCL: SAFETY AND EFFICACY RESULTS FROM THE SAFETY RUN-IN PERIOD OF THE PHASE 3 ECHELON-3 STUDY

Bibliographic Details
Main Authors:	N. L. Bartlett, C. A. Yasenchak, K. K. Ashraf, W. N. Harwin, J. Orcutt, P. Kuriakose, P. L. Zinzani, A. Mamidipalli, K. Fenton, C. Glenn, G. Nowakowski
Format:	Article
Language:	English
Published:	Wiley 2022-06-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000847576.88118.d6

Similar Items

Brentuximab vedotin with chemotherapy in adolescents and young adults with stage III or IV classical Hodgkin lymphoma in ECHELON-1
by: Howland E. Crosswell, et al.
Published: (2023-10-01)

Did brentuximab vedotin’s rise to the top ECHELON of Hodgkin therapeutics invalidate AETHERA results?
by: Mehdi Hamadani
Published: (2021-12-01)

Safety of Concurrent Radiation Therapy With Brentuximab Vedotin in the Treatment of Lymphoma
by: Susan Y. Wu, MD, et al.
Published: (2023-11-01)

Brentuximab vedotin induced uveitis
by: Stijn Therssen, M.D., et al.
Published: (2022-06-01)

The Phase 3 Study ECHELON-1 Evaluating Brentuximab Vedotin in Patients With Newly Diagnosed Hodgkin Lymphoma Leaves Important Questions Unanswered
by: Peter Borchmann, et al.
Published: (2018-06-01)

Safety and efficacy of brentuximab vedotin as a treatment for lymphoproliferative disorders in primary immunodeficiencies
by: Thomas Pincez, et al.
Published: (2020-06-01)

Brentuximab vedotin in pediatric Hodgkin lymphoma
by: Shuvadeep Ganguly, et al.
Published: (2022-01-01)

P089 (0137) POPULATION PHARMACOKINETIC (POPPK) MODELING AND EXPOSURE-RESPONSE (ER) ASSESSMENT OF BRENTUXIMAB VEDOTIN EFFICACY AND SAFETY IN PATIENTS WITH ADVANCED CLASSICAL HODGKIN LYMPHOMA (CHL) FROM THE PHASE 3 ECHELON-1 STUDY
Published: (2018-10-01)

S200: IMPROVED OVERALL SURVIVAL WITH FIRST-LINE BRENTUXIMAB VEDOTIN PLUS CHEMOTHERAPY IN PATIENTS WITH STAGE III/IV CLASSICAL HODGKIN LYMPHOMA: 6-YEAR ANALYSIS OF ECHELON-1
by: M. Hutchings, et al.
Published: (2022-06-01)

Brentuximab Vedotin Treatment for Primary Refractory Hodgkin Lymphoma
by: Hung-Bo Wu, et al.
Published: (2013-01-01)

Overall survival with brentuximab vedotin in advanced Hodgkin lymphoma
by: Shuvadeep Ganguly, et al.
Published: (2022-01-01)

Brentuximab vedotin for relapsed or refractory Hodgkin’s lymphoma
by: Chen R, et al.
Published: (2015-03-01)

The Evolving Role of Brentuximab Vedotin in Classical Hodgkin Lymphoma
by: Lai C, et al.
Published: (2019-12-01)

CD30-Positive Extracellular Vesicles Enable the Targeting of CD30-Negative DLBCL Cells by the CD30 Antibody-Drug Conjugate Brentuximab Vedotin
by: Liudmila Lobastova, et al.
Published: (2021-07-01)

Brentuximab vedotin is the first target drug in the treatment of hodgkin lymphoma
by: G. S. Tumyan
Published: (2018-11-01)

Brentuximab vedotin use in pediatric anaplastic large cell lymphoma
by: Jennifer E. Agrusa, et al.
Published: (2023-05-01)

Role of brentuximab vedotin in the treatment of relapsed or refractory Hodgkin lymphoma
by: Siddiqi T, et al.
Published: (2014-02-01)

P009: Improved Overall Survival with First-Line Brentuximab Vedotin plus Chemotherapy in Patients with Advanced Stage III/IV Classical Hodgkin Lymphoma: An Updated Analysis of ECHELON-1
by: Martin Hutchings, et al.
Published: (2022-10-01)

The Successful Use of Neo Adjuvant Brentuximab Vedotin in the Treatment of BIA-ALCL
by: Rebecca L. Allchin, et al.
Published: (2020-12-01)

Cutaneous Anaplastic Large-Cell Lymphoma with Dramatic Response to Brentuximab Vedotin
by: Mustafa Şahin, et al.
Published: (2021-02-01)

Improvement of Cutaneous Anaplastic Large Cell Lymphoma by Brentuximab Vedotin Monotherapy
by: Takashi Onaka, et al.
Published: (2018-05-01)

Immediate Response to Brentuximab Vedotin in a Patient with Localized MF-LCT
by: Agnieszka Giza, et al.
Published: (2023-07-01)

Rapid desensitization for brentuximab vedotin (Adceteris®) allergy: a case report
by: Attilio Di Girolamo, et al.
Published: (2018-10-01)

Hodgkin Lymphoma on Hemodialysis Successfully Treated with Extended Courses of Brentuximab Vedotin
by: Ayana Uchimura, et al.
Published: (2022-03-01)

Emerging Pharmacotherapy for Relapsed or Refractory Hodgkins Lymphoma: Focus on Brentuximab Vedotin
by: Michelle Furtado, et al.
Published: (2012-01-01)

P1064: BRENTUXIMAB VEDOTIN, NIVOLUMAB, DOXORUBICIN, AND DACARBAZINE FOR ADVANCED STAGE CLASSICAL HODGKIN LYMPHOMA: UPDATED EFFICACY AND SAFETY RESULTS FROM THE SINGLE ARM PHASE 2 STUDY
by: Chris Yasenchak, et al.
Published: (2023-08-01)

COST-EFFECTIVENESS ANALYSIS OF BRENTUXIMAB VEDOTIN IN ADULTS WITH RELAPSED OR REFRACTORY HODGKIN’S LYMPHOMA
by: G. R. Khachatryan, et al.
Published: (2016-04-01)

TARGETED THERAPY WITH BRENTUXIMAB VEDOTIN IN RELAPSED AND REFRACTORY FORMS OF CLASSICAL HODGKIN LYMPHOMA
by: E. A. Demina
Published: (2017-11-01)

Brentuximab vedotin therapy for cutaneous lesions in T-prolymphocytic leukemia: a case report
by: Jordan Senchak, et al.
Published: (2016-09-01)

Testing sensitivity to cd30 targeting via brentuximab vedotin in multiple myeloma
by: E. La Spina, et al.
Published: (2020-09-01)

CD30 - the head of TNF-family… or a successful story of brentuximab vedotin
by: Popović Lazar, et al.
Published: (2013-01-01)

Use of Brentuximab Vedotin in a Non-HIV Patient with Primary Effusion Lymphoma
by: Joana Ferra, et al.
Published: (2021-02-01)

Profile of brentuximab vedotin and its potential in the treatment of relapsed or refractory Hodgkin lymphoma
by: Illidge T, et al.
Published: (2012-05-01)

Potentials of brentuximab vedotin in the treatment of relapse/refractory cutaneous T-cell lymphomas: literature review and authors’ observation
by: L. G. Gorenkova, et al.
Published: (2019-07-01)

P072 (0038) FRONTLINE BRENTUXIMAB VEDOTIN PLUS CHEMOTHERAPY EXHIBITS SUPERIOR MODIFIED PROGRESSION-FREE SURVIVAL VS CHEMOTHERAPY ALONE IN PATIENTS WITH STAGE III OR IV HODGKIN LYMPHOMA: PHASE 3 ECHELON-1 STUDY
Published: (2018-10-01)

Inhibitors of ADAM10 reduce Hodgkin lymphoma cell growth in 3D microenvironments and enhance brentuximab-vedotin effect
by: Roberta Pece, et al.
Published: (2021-06-01)

SUCCESSFUL USE OF BRENTUXIMAB VEDOTIN IN THE TREATMENT OF PROGRESSIVE PERIPHERAL UNSPECIFIED T-CELL LYMPHOMA IN AN ELDERLY FEMALE PATIENT
by: L. G. Gorenkova, et al.
Published: (2017-06-01)

Hodgkin’s Lymphoma after Autologous Stem-Cell Transplantation: Effective Consolidation with Brentuximab Vedotin
by: Adrian Schmidt
Published: (2020-11-01)

Brentuximab Vedotin-induced Tumour Lysis Syndrome in Mycosis Fungoides: A Case Report
by: Berenika Olszewska, et al.
Published: (2024-11-01)

Brentuximab vedotin (Adcetris®) in therapy of system anaplastic large cell lymphoma. Case report
by: A. A. Semenova, et al.
Published: (2019-01-01)